share_log

紐曼思:截至二零二四年十二月三十一日止年度的年度業績公告

NUMANS: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024

HKEX ·  Mar 21 14:28

Summary by Moomoo AI

紐曼思健康食品於2024財年收益減少34.9%至人民幣2.775億元,年內溢利下跌53.0%至人民幣7,490萬元。毛利率維持在76.1%的較高水平,董事會建議派發末期股息每股人民幣5.00分。收入下滑主要受日本排放核污水引發消費者囤貨行為及中國經濟暫時下滑影響。公司主要產品藻油DHA貢獻96.1%的收入,銷量由191.8萬件降至127.6萬件。線上銷售渠道仍為主要銷售渠道,佔總收入80.5%。銷售及分銷開支減少至人民幣9,057萬元,行政開支維持在人民幣2,375萬元水平。展望未來,集團對中國營養品行業前景充滿信心,將在2025年加大營銷力度,通過線上線下相結合的全面營銷策略提高品牌認知度。公司已於2025年1月10日在港交所主板上市,全球發售籌資淨額約1.24億港元,將用於未來業務發展及加強營銷。
紐曼思健康食品於2024財年收益減少34.9%至人民幣2.775億元,年內溢利下跌53.0%至人民幣7,490萬元。毛利率維持在76.1%的較高水平,董事會建議派發末期股息每股人民幣5.00分。收入下滑主要受日本排放核污水引發消費者囤貨行為及中國經濟暫時下滑影響。公司主要產品藻油DHA貢獻96.1%的收入,銷量由191.8萬件降至127.6萬件。線上銷售渠道仍為主要銷售渠道,佔總收入80.5%。銷售及分銷開支減少至人民幣9,057萬元,行政開支維持在人民幣2,375萬元水平。展望未來,集團對中國營養品行業前景充滿信心,將在2025年加大營銷力度,通過線上線下相結合的全面營銷策略提高品牌認知度。公司已於2025年1月10日在港交所主板上市,全球發售籌資淨額約1.24億港元,將用於未來業務發展及加強營銷。
Newman Health Food's revenue for the fiscal year 2024 decreased by 34.9% to 0.2775 billion RMB, with profit falling by 53.0% to 74.9 million RMB. The gross margin remained at a high level of 76.1%, and the Board of Directors recommended a final dividend of 5.00 RMB cents per share. The revenue decline was mainly impacted by consumers stockpiling due to Japan's discharge of nuclear wastewater and a temporary downturn in the Chinese economy.The company's main product, algal oil DHA, contributed 96.1% of revenue, with sales dropping from 1.918 million units to 1.276 million units. Online sales channels remained the primary sales channel, accounting for 80.5% of total revenue. Sales and distribution expenses decreased to 90.57 million RMB, while administrative expenses remained at 23.75 million RMB.Looking ahead, the...Show More
Newman Health Food's revenue for the fiscal year 2024 decreased by 34.9% to 0.2775 billion RMB, with profit falling by 53.0% to 74.9 million RMB. The gross margin remained at a high level of 76.1%, and the Board of Directors recommended a final dividend of 5.00 RMB cents per share. The revenue decline was mainly impacted by consumers stockpiling due to Japan's discharge of nuclear wastewater and a temporary downturn in the Chinese economy.The company's main product, algal oil DHA, contributed 96.1% of revenue, with sales dropping from 1.918 million units to 1.276 million units. Online sales channels remained the primary sales channel, accounting for 80.5% of total revenue. Sales and distribution expenses decreased to 90.57 million RMB, while administrative expenses remained at 23.75 million RMB.Looking ahead, the group is confident about the prospects of the nutritional supplement industry in China and plans to increase marketing efforts in 2025 to enhance brand recognition through a comprehensive marketing strategy that combines online and offline efforts. The company was listed on the Main Board of the Hong Kong Stock Exchange on January 10, 2025, with a global fundraising net amount of approximately 0.124 billion HKD, which will be used for future Business development and enhancing marketing.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 222

Recommended

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.